Presseaussendungen zu "Aplidin"

40 Aussendungen

PharmaMar Reports Positive Phase II Results on Aplidin(R) in Patients With Advanced Multiple Myeloma at ASH

PharmaMar today announces the results of the Aplidin(R) Phase II trial which were presented at the American Society of Hematology 47th Annual Meeting in Atlanta, Georgia, USA, on Sunday 11 December.

OTE0003
12.12.2005 12:18

PharmaMar Presents Pharmacogenomic Data on Yondelis(R) at CTOS

PharmaMar announces the presentation of data from two research projects at the 11th Annual CTOS (Connective Tissue Oncology Society) Meeting, which took place in Florida, USA, from November 19-21, 2005.

OTE0004
22.11.2005 09:26

Zeltia and PharmaMar: R&D Spend Increases by 10% in the 9 Months to September 2005

Zeltia S.A. (ZEL SM; ZEL.MC), Spanish pioneer and leader in biotechnology, announces 9 months results to September 2005.

OTE0001
27.10.2005 09:28

PharmaMar's sechstes neues Präparat, PM02734, in klinischem Versuch gestartet

PharmaMar gibt heute bekannt, dass PM02734, ein aus dem Meer gewonnenes Präparat, in den klinischen Phase-I-Versuch für die Behandlung von soliden Tumoren eingetreten ist.

OTS0013
04.10.2005 08:28

Aplidin(R) Commences Combination Trials

- Further Steps in the Development of Aplidin(R) in Melanoma in First Line Therapy

OTE0002
15.09.2005 08:30

PharmaMar Reinforces its Clinical Development Team With the Appointment of Dr Pedro Santabárbara

- In his Previous Position he was Vice President, Clinical Research Oncology at OSI Pharmaceuticals in the US

OTE0002
11.07.2005 17:40

Zeltia Raises EUR 65 Million Through Institutional Placing

Zeltia S.A.(ZEL SM; ZEL.MC), the Spanish biotechnology company, today announces that it has raised Eur 65 million of new funds through a private placement of 10.75 million new ordinary shares with qualified …

OTE0001
23.06.2005 09:24

Zeltia to Raise New Funds Through Institutional Placing

Zeltia S.A, the Spanish consumer chemicals and biotechnology group announces today that its Board of Directors has authorized a capital increase through a private placement with qualified international …

OTE0009
21.06.2005 19:12
OTE0005
28.04.2005 09:50

PharmaMar Presents 13 Posters at AACR Highlighting Clinical and Preclinical Development Pipeline

PharmaMar today announces the presentation of thirteen posters highlighting advances with its clinical and preclinical compounds at the 96th Annual Meeting of the American Association for Cancer Research …

OTE0003
18.04.2005 08:37

YONDELIS(R) Granted Orphan Drug Designation by the U.S. FDA For The Treatment of Ovarian Cancer

PharmaMar announced today that its marine-derived anti-cancer drug, YONDELIS(R) (trabectedin), has been granted Orphan Drug Designation by the U.S.

OTE0003
07.04.2005 15:30
OTE0002
24.02.2005 08:15

Aplidin(R) Commences Phase II Clinical Trials in Prostate and Bladder Cancers

PharmaMar announces that its second most advanced marine-derived anti-tumour agent, Aplidin(R), has commenced Phase II clinical trials in both prostate and bladder cancers.

OTE0002
17.02.2005 09:26

PharmaMar's Fifth Novel Compound, Zalypsis(R), Enters Clinical Development

PharmaMar announced today that Zalypsis(R) (PM00104/50), its fifth new marine derived compound, has begun Phase I clinical trials, already in patients, for the treatment of solid tumours.

OTE0003
17.01.2005 08:25